The purpose of this article is to review both routine T2-weighted and new MRI techniques in the imaging of prostate cancer (PCa) for focal therapy. T2-weighted imaging, knowledge of MRI prostate zonal anatomy, cancer morphology, and intraprostatic tumor spread remain essential for clinical PCa imaging; however, new techniques, such as dynamic contrast-enhanced MRI, diffusion-weighted imaging, and magnetic resonance spectroscopic imaging yield significant improvements in identification and volume estimation. Potential advantages of 3 Tesla MRI are adequate imaging without an endorectal coil. Future studies should work toward helping define standard, reproducible approaches to multimodality MRI and image reporting for research and clinical practice.
Get full access to this article
View all access options for this article.
References
1.
StameyTA, CaldwellM, McNealJEet al.The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?J Urol, 2004; 172:1297–1301.
2.
MazaheriY, Shukla-DaveA, HricakHet al.Prostate cancer: Identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging—correlation with pathologic findings. Radiology, 2008; 246:480–488.
3.
deSouzaNM, RichesSF, VanasNJet al.Diffusion-weighted magnetic resonance imaging: A potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol, 2008; 63:774–782.
4.
KumarR, NayyarR, KumarVet al.Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: A follow-up study. Urology, 2008; 72:859–863.
5.
CascianiE, PolettiniE, CarmeniniEet al.Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol, 2008; 190:1187–1192.
6.
KirkhamAP, EmbertonM, HohIMet al.MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology, 2008; 246:833–844.
7.
HaiderMA, ChungP, SweetJet al.Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys, 2008; 70:425–430.
8.
BouyéS, PotironE, PuechPet al.Transition zone and anterior stromal prostate cancers: Zone of origin and intraprostatic patterns of spread at histopathology. Prostate, 2009; 69:105–113.
9.
HaffnerJ, PotironE, BouyéSet al.Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology. Prostate, 2009; 69:276–282.
10.
WangL, ZhangJ, SchwartzLHet al.Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol, 2007; 188:99–104.
11.
AkinO, SalaE, MoskowitzCSet al.Transition zone prostate cancers: Features, detection, localization, and staging at endorectal MR imaging. Radiology, 2006; 239:784–792.
12.
MulleradM, HricakH, WangLet al.Prostate cancer: Detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology, 2004; 232:140–146.
13.
FüttererJJ, HeijminkSW, ScheenenTWet al.Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 2006; 241:449–458.
14.
GirouinN, Mége-LechevallierF, Tonina SenesAet al.Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: Is it reasonable?Eur Radiol, 2007; 17:1498–1509.
15.
PuechP, PotironE, LemaitreLet al.Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology, 2009; 74:1094–1099.
16.
VillersA, PuechP, MoutonDet al.Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: Correlation with radical prostatectomy findings. J Urol, 2006; 176:2432–2437.
17.
YuJS, ChungJJ, HongSWet al.Prostate cancer: Added value of subtraction dynamic imaging in 3T magnetic resonance imaging with a phased-array body coil. Yonsei Med J, 2008; 49:765–774.
18.
EngelbrechtMR, HuismanHJ, LaheijRJet al.Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology, 2003; 229:248–254.
19.
HaiderMA, van der KwastTH, TanguayJet al.Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol, 2007; 189:323–328.
20.
MiaoH, FukatsuH, IshigakiT. Prostate cancer detection with 3-T MRI: Comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol, 2007; 61:297–302.
21.
LimHK, KimJK, KimKA, ChoKS. Prostate cancer: Apparent diffusion coefficient map with T2-weighted images for detection—a multireader study. Radiology, 2009; 250:145–151.
22.
ParkBK, LeeHM, KimCKet al.Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol, 2008; 43:789–793.
23.
YoshimitsuK, KiyoshimaK, IrieHet al.Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: Correlation with stepwise histopathology. J Magn Reson Imaging, 2008; 27:132–139.
24.
YoshizakoT, WadaA, HayashiTet al.Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol, 2008; 49:1207–1213.
25.
ChenM, DangHD, WangJYet al.Prostate cancer detection: Comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol, 2008; 49:602–610.
26.
KajiharaH, HayashidaY, MurakamiRet al.Usefulness of diffusion-weighted imaging in the localization of prostate cancer. Int J Radiat Oncol Biol Phys, 2009; 74:399–403.
27.
deSouzaNM, ReinsbergSA, ScurrEDet al.Magnetic resonance imaging in prostate cancer: The value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol, 2007; 80:90–95.
28.
ZelhofB, PicklesM, LineyGet al.Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int, 2009; 103:883–888.
29.
LangerDL, van der KwastTH, EvansAJet al.Intermixed normal tissue within prostate cancer: Effect on MR imaging measurements of apparent diffusion coefficient and T2—sparse versus dense cancers. Radiology, 2008; 249:900–908.
30.
GürsesB, KabakciN, KovanlikayaAet al.Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol, 2008; 18:716–721.
31.
ManentiG, CarlaniM, MancinoSet al.Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol, 2007; 42:412–419.
32.
Morakkabati-SpitzN, BastianPJ, GiesekeJet al.MR imaging of the prostate at 3.0T with external phased array coil—preliminary results. Eur J Med Res, 2008; 13:287–91.
33.
CarlaniM, MancinoS, BonannoEet al.Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: Preliminary experience. Radiol Med (Torino), 2008; 113:670–688.
34.
VilleirsGM, OosterlinckW, VanherrewegheE, De MeerleerGO. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol, 2008Dec 10. Epub ahead of print.
35.
WestphalenAC, CoakleyFV, QayyumAet al.Peripheral zone prostate cancer: Accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology, 2008; 246:177–184.
36.
WangP, GuoYM, LiuMet al.A meta-analysis of the accuracy of prostate cancer studies which use magnetic resonance spectroscopy as a diagnostic tool. Korean J Radiol, 2008; 9:432–438.
37.
UmbehrM, BachmannLM, HeldUet al.Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: A systematic review and meta-analysis. Eur Urol, 2009; 55:575–590.
38.
PuechP, HugloD, PetytGet al.Imaging of organ-confined prostate cancer: Functional ultrasound, MRI and PET/computed tomography. Curr Opin Urol, 2009; 19:168–176.
39.
KurhanewiczJ, VigneronD, CarrollP, CoakleyF. Multiparametric magnetic resonance imaging in prostate cancer: Present and future. Curr Opin Urol, 2008; 18:71–77.
40.
SciarraA, PanebiancoV, SalcicciaSet al.Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol, 2008; 54:589–600.
41.
TamadaT, SoneT, JoYet al.Prostate cancer: Relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. Radiology, 2008; 248:531–539.
42.
PrandoA. Prostate cancer: Identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Int Braz J Urol, 2008; 34:105–106.
43.
ReinsbergSA, PayneGS, RichesSFet al.Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol, 2007; 188:91–98.
44.
KimCK, ParkBK. Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr, 2008; 32:163–172.
45.
ParkBK, KimB, KimCKet al.Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr, 2007; 31:534–538.
